Theravance Biopharma (TBPH) Free Cash Flow (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Free Cash Flow of $73.3 million for Q1 2026, up 70.26% year-over-year from $43.0 million in Q1 2025, and up 1306.83% quarter-over-quarter from -$6.1 million in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) Free Cash Flow (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Free Cash Flow for 14 consecutive years, with $73.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 70.26% year-over-year to $73.3 million; the TTM figure through Mar 2026 stood at $268.8 million (up 732.5% YoY), while the FY2025 annual figure was $238.5 million, up 2109.77% from the prior year.
- Free Cash Flow advanced to $73.3 million in Q1 2026 per TBPH's latest filing, from -$6.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $208.1 million in Q2 2025 and bottomed at -$26.3 million in Q1 2022.
- Historically, Free Cash Flow has averaged $15.7 million across 5 years, with a median of -$4.5 million in 2024.
- On a YoY basis, Free Cash Flow climbed as much as 4774.77% in 2025 and fell as far as 456.04% in 2025.
- Theravance Biopharma's Free Cash Flow stood at $54.6 million in 2022, then sank by 102.8% to -$1.5 million in 2023, then grew by 28.67% to -$1.1 million in 2024, then sank by 456.04% to -$6.1 million in 2025, then jumped by 1306.83% to $73.3 million in 2026.
- Business Quant data shows TBPH's Free Cash Flow at $73.3 million in Q1 2026, -$6.1 million in Q4 2025, and -$6.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Theravance Biopharma | 882.21 Mn | 494.56 Mn | - | -6.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.97 Mn |
| Mar 31, 2026 | 73.28 Mn |
| Dec 31, 2025 | -6.07 Mn |
| Sep 30, 2025 | -6.51 Mn |
| Jun 30, 2025 | 208.07 Mn |
| Mar 31, 2025 | 43.04 Mn |
| Dec 31, 2024 | -1.09 Mn |
| Sep 30, 2024 | -5.21 Mn |
| Jun 30, 2024 | -4.45 Mn |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | -1.53 Mn |
| Sep 30, 2023 | -2.51 Mn |
| Jun 30, 2023 | -13.29 Mn |
| Mar 31, 2023 | -12.16 Mn |
| Dec 31, 2022 | -124.32 Mn |
| Sep 30, 2022 | -22.08 Mn |
| Jun 30, 2022 | -14.23 Mn |
| Mar 31, 2022 | -26.93 Mn |
| Dec 31, 2021 | -45.69 Mn |
| Sep 30, 2021 | -71.59 Mn |